Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
6(33%)
Results Posted
0%(0 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_1
1
6%
Ph not_applicable
8
44%
Ph phase_2
3
17%
Ph phase_3
2
11%

Phase Distribution

1

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
1(7.1%)
Phase 2Efficacy & side effects
3(21.4%)
Phase 3Large-scale testing
2(14.3%)
N/ANon-phased studies
8(57.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

6

trials recruiting

Total Trials

18

all time

Status Distribution
Active(8)
Completed(7)
Terminated(2)
Other(1)

Detailed Status

Completed7
Recruiting6
Not yet recruiting2
Withdrawn1
Suspended1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
6
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (7.1%)
Phase 23 (21.4%)
Phase 32 (14.3%)
N/A8 (57.1%)

Trials by Status

completed739%
withdrawn16%
recruiting633%
suspended16%
terminated16%
not_yet_recruiting211%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT04851119Phase 1

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Recruiting
NCT05876923Not Applicable

The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients

Recruiting
NCT07466498Phase 2

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

Not Yet Recruiting
NCT06671912Phase 3

Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial

Suspended
NCT06983899Not Applicable

Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial

Recruiting
NCT05838716Phase 3

Vitamin D for Prostate Endocrine Therapy

Recruiting
NCT06039371Phase 2

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Recruiting
NCT05893940Not Applicable

Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients

Recruiting
NCT04516122

Bone Loss in Melanoma Survivors Receiving Immunotherapy

Terminated
NCT00963417Not Applicable

Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02

Completed
NCT02592356Not Applicable

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Completed
NCT06129851Phase 2

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

Not Yet Recruiting
NCT02704377Not Applicable

Quality of Life and Supportive Care Preferences Following Radiation Therapy in Prostate Cancer Survivors

Completed
NCT03811873Not Applicable

Assessment of Vertebral Fracture Risk for First Time Liver Transplant Candidates

Completed
NCT04062955Not Applicable

Effects of Alternative Healthy Eating Index-Based Diet on Inflammatory Markers and Breast Density in Healthy Participants

Completed
NCT02922478

Role of Comorbidities in Chronic Heart Failure Study

Completed
NCT00873808

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

Withdrawn
NCT00176579

Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer

Completed

All 18 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
18